Vincent A. Miller focuses on Internal medicine, Lung cancer, Oncology, Cancer research and Erlotinib. His biological study spans a wide range of topics, including Endocrinology and Surgery. His studies in Lung cancer integrate themes in fields like Cancer, Adenocarcinoma, Carboplatin, Gastroenterology and EGFR inhibitors.
His research integrates issues of Hazard ratio, KRAS and Carcinoma, Pathology in his study of Oncology. His work carried out in the field of Cancer research brings together such families of science as Bioinformatics, Mutation, Tyrosine kinase, Anaplastic lymphoma kinase and Kinase. His Erlotinib research includes themes of T790M, Pharmacology and Gefitinib.
His primary scientific interests are in Internal medicine, Oncology, Cancer research, Cancer and Lung cancer. While the research belongs to areas of Internal medicine, Vincent A. Miller spends his time largely on the problem of Bioinformatics, intersecting his research to questions surrounding Colorectal cancer. His study looks at the relationship between Oncology and topics such as KRAS, which overlap with CDKN2A.
His work in Cancer research covers topics such as Gene which are related to areas like Ligation. Vincent A. Miller interconnects Phases of clinical research, Carcinoma, Pharmacology and Docetaxel in the investigation of issues within Lung cancer. His Erlotinib research is multidisciplinary, relying on both T790M and Gefitinib.
His primary areas of investigation include Cancer research, Internal medicine, Oncology, Genomic profiling and Cancer. His Cancer research study integrates concerns from other disciplines, such as Mutation, Gene, Microsatellite instability, Lung cancer and Immunotherapy. His Internal medicine research is multidisciplinary, incorporating perspectives in Precision medicine and MEDLINE.
The Oncology study combines topics in areas such as KRAS, Colorectal cancer, Clinical trial and CDKN2A. His Genomic profiling research incorporates elements of Liquid biopsy, Malignancy, Pathology and Computational biology. His work deals with themes such as Biomarker, Blockade, PI3K/AKT/mTOR pathway and Allele frequency, which intersect with Cancer.
His primary scientific interests are in Cancer research, Internal medicine, Oncology, Cancer and Gene. The concepts of his Cancer research study are interwoven with issues in Mutation, MEK inhibitor, Carcinoma, Lung cancer and Kinase. Vincent A. Miller works mostly in the field of Lung cancer, limiting it down to concerns involving Targeted therapy and, occasionally, RNA.
His Internal medicine study frequently draws connections between adjacent fields such as Microsatellite instability. His Oncology research includes elements of Prospective cohort study, Cohort and Gene expression profiling. He has researched Cancer in several fields, including Concordance and Pathology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
William Pao;Vincent Miller;Maureen Zakowski;Jennifer Doherty.
Proceedings of the National Academy of Sciences of the United States of America (2004)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson.
Journal of Thoracic Oncology (2011)
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William Pao;Vincent A. Miller;Katerina A Politi;Gregory J. Riely.
PLOS Medicine (2005)
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Roy S. Herbst;Giuseppe Giaccone;Joan H. Schiller;Ronald B. Natale.
Journal of Clinical Oncology (2004)
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giuseppe Giaccone;Roy S. Herbst;Christian Manegold;Giorgio Scagliotti.
Journal of Clinical Oncology (2004)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima.
Clinical Cancer Research (2013)
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
David A. Eberhard;Bruce E. Johnson;Lukas C. Amler;Audrey D. Goddard.
Journal of Clinical Oncology (2005)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers;Caitlin F. Connelly;David Fabrizio.
Genome Medicine (2017)
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
Frank V. Fossella;Russell DeVore;Ronald N. Kerr;Jeffrey Crawford.
Journal of Clinical Oncology (2000)
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
William Pao;Theresa Y Wang;Gregory J Riely;Vincent A Miller.
PLOS Medicine (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: